Your search for oral corticosteroids returned 5 results

The FDA’s Fast Track process allows for expedited review of drugs that are expected to fill an unmet need.

Efzofitimod is a potential first-in-class selective modulator of neuropilin-2 that is designed to downregulate innate and adaptive immune responses in inflammatory disease states.

The BLA submission is supported by data from the PATHFINDER clinical program.

Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.

Vamorolone is a first-in-class dissociative steroidal drug that retains the anti-inflammatory activity of corticosteroids but with a novel mechanism of action.